Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis

Abstract

ContextThe hepatitis B virus (HBV) is a major global public health problem, affecting more than 2 billion people worldwide. Accurate and updated data on HBV prevalence is important for further planning to control the infection. The aim of this study was to update the prevalence estimate of HBV infection in the general population of Iran.Evidence AcquisitionA systematic review was done for data on the prevalence of HBV infection in the general Iranian population published between Jan. 1, 1990, and Jan. 1, 2016, in both international and national databases, including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, and Magiran. All papers with clearly described time and location of the study, proper sampling strategies, and proper analysis methods were included in the present study. Data were extracted by two independent reviewers. Prevalence of HBV infection with a 95% confidence interval (CI) was calculated using Stata software, version 13.ResultsThe polled estimated prevalence of HBV infection in the general population of Iran was 2.2 % (95% CI: 1.9% - 2.6%). The highest prevalence of HBV infection (8.9%, 95% CI: 7.6% - 10.2%) was reported from Golestan province, and the lowest prevalence (0.7%, 95% CI: 0.4% - 1.1%) was seen in Kermanshah province. The prevalence of HBV infection was estimated at 3% (95% CI: 2.2% - 3.8%) for Iranian males and 1.7% (95% CI: 1.2% - 2.3%) for Iranian females. The prevalence of HBV infection in the general population of Iran was 2.9% (95% CI: 2.5% - 3.4%) before 2010 and 1.3% (95% CI: 0.9% - 1.7%) after 2010.ConclusionsIn total, Iran was classified within the low–intermediate HBV prevalence areas (2% - 4%), while according to recent data (after 2010), Iran was classified within the low HBV prevalence areas (< 2%), indicating that preventive measures conducted in Iran have been effective.

Comparative analysis of oral Candida albicans rate in healthy people and people with HBSAg+ referring to blood transfusion organization in Ahvaz in 2008

“…Hepatitis B virus is one of the main problem of global public health (1-7) by which more than 2 billion people has been infected in whole world (2,5). In spite of easy access to very effective vaccine for HBV, it is estimated that there are 350 million people that are transporter of this disease globally (2,8).…”

“…Death rate estimated more than 780000 years in a year (2). Prevalence rate of HBV infection is different in whole world.…”

“…In spite of easy access to very effective vaccine for HBV, it is estimated that there are 350 million people that are transporter of this disease globally (2,8). People who are infected by DOI: http://dx.doi.org/10.22192/ijcrcps.2017.04.03.006…”

“…Based on study in 2016, prevalence rate of HBV in Iran is 3% (5). But regional studies in different provinces reported prevalence rate as 1/7% in last decade (2). Currently there is no assured medication against infection of HBV (9).…”

Public Awareness Campaign and Knowledge of Iranian (Bio)Medical Students Regarding Hepatitis B and C Infections

“…Prevalence of hepatitis B virus (HBV) infection is low in Iran, as reported in less than 2% of the general population (1). The infantile vaccination program established in 1993, along with the vaccination of highrisk groups, has shown positive impacts on decreasing the prevalence of HBV infection in the past decade (2).…”